- Home
- STR vs EWTX Comparison
STR vs EWTX Comparison
Compare STR & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STR
- EWTX
- Stock Information
- Founded
- STR 2016
- EWTX 2017
- Country
- STR United States
- EWTX United States
- Employees
- STR N/A
- EWTX N/A
- Industry
- STR Oil & Gas Production
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- STR Energy
- EWTX Health Care
- Exchange
- STR Nasdaq
- EWTX Nasdaq
- Market Cap
- STR 1.4B
- EWTX 1.5B
- IPO Year
- STR N/A
- EWTX 2021
- Fundamental
- Price
- STR $18.64
- EWTX $13.93
- Analyst Decision
- STR Buy
- EWTX Buy
- Analyst Count
- STR 6
- EWTX 8
- Target Price
- STR $26.80
- EWTX $41.13
- AVG Volume (30 Days)
- STR 1.1M
- EWTX 633.0K
- Earning Date
- STR 08-04-2025
- EWTX 08-07-2025
- Dividend Yield
- STR 7.50%
- EWTX N/A
- EPS Growth
- STR N/A
- EWTX N/A
- EPS
- STR 0.44
- EWTX N/A
- Revenue
- STR $613,649,000.00
- EWTX N/A
- Revenue This Year
- STR N/A
- EWTX N/A
- Revenue Next Year
- STR N/A
- EWTX N/A
- P/E Ratio
- STR $42.40
- EWTX N/A
- Revenue Growth
- STR N/A
- EWTX N/A
- 52 Week Low
- STR $14.58
- EWTX $10.60
- 52 Week High
- STR $25.52
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- STR 49.30
- EWTX 52.63
- Support Level
- STR $17.98
- EWTX $12.30
- Resistance Level
- STR $18.89
- EWTX $14.11
- Average True Range (ATR)
- STR 0.52
- EWTX 0.73
- MACD
- STR 0.05
- EWTX 0.00
- Stochastic Oscillator
- STR 55.49
- EWTX 53.80
About STR Sitio Royalties Corp.
Sitio Royalties Corp is a pure-play mineral and royalty company. The group focuses on investing in mineral and royalty interests in the Permian and other productive U.S. oil basins.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.